[go: up one dir, main page]

MX9206844A - COMPOUNDS, COMPOSITIONS AND METHODS FOR JOINING SUBSTANCES OF BIOLOGICAL INFLUENCE TO BIOPARTICLE SURFACE MEMBRANES - Google Patents

COMPOUNDS, COMPOSITIONS AND METHODS FOR JOINING SUBSTANCES OF BIOLOGICAL INFLUENCE TO BIOPARTICLE SURFACE MEMBRANES

Info

Publication number
MX9206844A
MX9206844A MX9206844A MX9206844A MX9206844A MX 9206844 A MX9206844 A MX 9206844A MX 9206844 A MX9206844 A MX 9206844A MX 9206844 A MX9206844 A MX 9206844A MX 9206844 A MX9206844 A MX 9206844A
Authority
MX
Mexico
Prior art keywords
compounds
compositions
methods
surface membranes
biological influence
Prior art date
Application number
MX9206844A
Other languages
Spanish (es)
Inventor
Gregory A Kopia
Paul K Horan
Brian D Gray
David E Troutner
Katharine A Muirhead
Kamleshkumar A Sheth
Chia-En Lin
Yu Susan Z Zhizhou
Lever Kwamena E Baidoo Slezak
Original Assignee
Zynaxis Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/884,432 external-priority patent/US5667764A/en
Application filed by Zynaxis Technologies Inc filed Critical Zynaxis Technologies Inc
Publication of MX9206844A publication Critical patent/MX9206844A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1258—Pills, tablets, lozenges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan compuestos que tienen la capacidad de unir substancias terapéuticamente activas a partículas bio-compatible que contienen lípidos, tales como células o virus. Estos compuestos incluyen una porción de influencia biológica, que comprende una substancia terapéuticamente activa, la cual está enlazada a través de porción de enlazamiento a cuando menos un substituyente hidrocarburo, seleccionado de manera que el compuesto sea lo suficientemente no polar, para impartir una capacidad de unión del lípido al compuesto.Compounds are provided that have the ability to bind therapeutically active substances to lipid-containing biocompatible particles, such as cells or viruses. These compounds include a biologically influencing moiety, which comprises a therapeutically active substance, which is bonded through the moiety bonding to at least one hydrocarbon substituent, selected such that the compound is sufficiently nonpolar, to impart an ability to binding of lipid to compound.

MX9206844A 1991-11-27 1992-11-27 COMPOUNDS, COMPOSITIONS AND METHODS FOR JOINING SUBSTANCES OF BIOLOGICAL INFLUENCE TO BIOPARTICLE SURFACE MEMBRANES MX9206844A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79893691A 1991-11-27 1991-11-27
US07/884,432 US5667764A (en) 1988-05-02 1992-05-15 Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles

Publications (1)

Publication Number Publication Date
MX9206844A true MX9206844A (en) 1993-07-01

Family

ID=27122052

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9206844A MX9206844A (en) 1991-11-27 1992-11-27 COMPOUNDS, COMPOSITIONS AND METHODS FOR JOINING SUBSTANCES OF BIOLOGICAL INFLUENCE TO BIOPARTICLE SURFACE MEMBRANES

Country Status (10)

Country Link
EP (1) EP0643706A1 (en)
JP (2) JP3682974B2 (en)
CN (1) CN1074911A (en)
AU (2) AU3221993A (en)
CA (1) CA2124329C (en)
IL (1) IL103874A0 (en)
MX (1) MX9206844A (en)
NZ (1) NZ245271A (en)
PH (1) PH31676A (en)
WO (1) WO1993011120A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE339975T1 (en) † 1993-07-19 2006-10-15 Angiotech Pharm Inc ANTI-ANGIOGENIC STENT AND METHOD FOR THE PRODUCTION THEREOF
ES2210258T5 (en) 1993-07-29 2009-01-16 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services PROCEDURE OF TREATMENT OF ATEROSCLEROSIS OR RESTENOSIS USING A STABILIZING AGENT OF MICROTUBLES.
US5480901A (en) * 1994-10-07 1996-01-02 Zynaxis, Inc. Method for reducing unwanted cellular adhesions
US6492332B1 (en) 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
US6004536A (en) * 1995-11-14 1999-12-21 Molecular Probes, Inc. Lipophilic cyanine dyes with enchanced aqueous solubilty
WO1997024459A1 (en) * 1995-12-29 1997-07-10 Phanos Technologoes, Inc. Method for reducing unwanted cellular adhesions
US5871436A (en) * 1996-07-19 1999-02-16 Advanced Cardiovascular Systems, Inc. Radiation therapy method and device
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
WO1998043618A2 (en) * 1997-03-31 1998-10-08 Neorx Corporation Use of cytoskeletal inhibitors for the prevention of restenosis
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US20040254635A1 (en) 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US7045305B1 (en) * 1998-04-08 2006-05-16 The Regents Of The University Of California Methods and reagents for targeting organic compounds to selected cellular locations
US6120847A (en) * 1999-01-08 2000-09-19 Scimed Life Systems, Inc. Surface treatment method for stent coating
US6333347B1 (en) 1999-01-29 2001-12-25 Angiotech Pharmaceuticals & Advanced Research Tech Intrapericardial delivery of anti-microtubule agents
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
US6156373A (en) 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
NZ517188A (en) * 1999-08-23 2003-11-28 Angiogene Inc Radioactively coated device and method of making same for preventing restenosis
CO5261573A1 (en) 1999-11-19 2003-03-31 Novartis Ag DERIVATIVES OF BENZOXA AND BEZOTIAZOL, COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THEM AND PROCESS FOR THE PREPARATION OF THE MENTIONED COMPOSITION
IT1319168B1 (en) * 2000-03-17 2003-09-26 Indena Spa ANTI-CANCER CONDENSATION DERIVATIVES, THEIR METHOD OF PREPARATION AND FORMULATIONS CONTAINING THEM.
IL155107A0 (en) 2000-10-16 2003-10-31 Conor Medsystems Inc Expandable medical device for delivery of beneficial agent
DE10115740A1 (en) 2001-03-26 2002-10-02 Ulrich Speck Preparation for restenosis prophylaxis
DE10244847A1 (en) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medical device for drug delivery
US7776529B2 (en) 2003-12-05 2010-08-17 Life Technologies Corporation Methine-substituted cyanine dye compounds
KR20070091609A (en) 2004-11-22 2007-09-11 지이 헬스케어 에이에스 Contrast Agents for Targeting Extracellular Matrix
US9050393B2 (en) 2005-02-08 2015-06-09 Bruce N. Saffran Medical devices and methods for modulation of physiology using device-based surface chemistry
EP1885718B1 (en) 2005-05-11 2017-03-15 Life Technologies Corporation Fluorescent chemical compounds having high selectivity for double stranded dna, and methods for their use
US8114429B2 (en) 2008-09-15 2012-02-14 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8257722B2 (en) 2008-09-15 2012-09-04 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US9198968B2 (en) 2008-09-15 2015-12-01 The Spectranetics Corporation Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
TWI637992B (en) * 2013-11-26 2018-10-11 住友化學股份有限公司 Rubber composition and vulcanization aid
US10525171B2 (en) 2014-01-24 2020-01-07 The Spectranetics Corporation Coatings for medical devices
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
US10975060B2 (en) 2016-11-28 2021-04-13 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
EP3883613A1 (en) 2018-11-23 2021-09-29 Bayer Aktiengesellschaft Formulation of contrast media and process of preparation thereof
JP7423888B2 (en) * 2019-11-22 2024-01-30 株式会社同仁化学研究所 Dye for staining lipid bilayer membranes and method for staining lipid bilayer membranes using the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1523965A (en) * 1976-03-19 1978-09-06 Ici Ltd Pharmaceutical compositions containing steroids
DE3170134D1 (en) * 1980-09-02 1985-05-30 Fuji Photo Film Co Ltd Method for immunochemical measurement
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4751219A (en) * 1985-02-05 1988-06-14 Nederlandse Centrale Organisatie Voor Toegepast-Natuur-Wetenschappelijk Onderzoek Synthetic glycolipides, a process for the preparation thereof and several uses for these synthetic glycolipides
US4762701A (en) * 1986-10-31 1988-08-09 Smithkline Beckman Corporation In vivo cellular tracking
US4783401A (en) * 1986-10-31 1988-11-08 Smithkline Beckman Corporation Viable cell labelling
US4906749A (en) * 1987-06-30 1990-03-06 Viomedics Inc. Cyclic anhydride derivatives of chromophors
EP0396626A1 (en) * 1988-01-19 1990-11-14 Board Of Regents, The University Of Texas System Glycosides, liposomal compositions thereof, and methods for their use
JP3038339B2 (en) * 1988-05-02 2000-05-08 ザイナクシス・テクノロジーズ・インコーポレーテッド Compounds that bind bioaffecting substances to the surface membrane of bioparticles
US5149794A (en) * 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting

Also Published As

Publication number Publication date
CA2124329A1 (en) 1993-06-10
JPH08502719A (en) 1996-03-26
JP4095847B2 (en) 2008-06-04
WO1993011120A1 (en) 1993-06-10
AU1991497A (en) 1997-07-10
CN1074911A (en) 1993-08-04
CA2124329C (en) 2008-11-18
JP3682974B2 (en) 2005-08-17
EP0643706A4 (en) 1994-12-27
AU3221993A (en) 1993-06-28
JP2003026657A (en) 2003-01-29
IL103874A0 (en) 1993-04-04
PH31676A (en) 1999-01-18
NZ245271A (en) 1996-03-26
EP0643706A1 (en) 1995-03-22

Similar Documents

Publication Publication Date Title
MX9206844A (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR JOINING SUBSTANCES OF BIOLOGICAL INFLUENCE TO BIOPARTICLE SURFACE MEMBRANES
Pickett et al. Initiation of phospholipase A2 activity in human platelets by the calcium ion ionophore A23187
EA200201042A1 (en) METHOD OF TREATMENT USING LJAND-IMMUNOGEN CONJUGATES
MX168497B (en) AFFINITY TANGENTIAL FLOW ULTRAFILTRATION
AR061222A1 (en) DERIVATIVES OF 2-OXO-PIRIDINA, 2-OXO-QUINOLINA AND 2-OXO-ISOQUINOLINA, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THE USE OF THE SAME IN MEDICATIONS TO TREAT DISEASES MEDIATED BY SCD.
DE69832375D1 (en) METHODS OF USE OF MACROCYCLIC LACTONS AS A MEANS FOR THE REVERSAL OF MULTIPLE MEDICATION RESISTANCE IN CANCER AND OTHER CELLS
EA200500300A1 (en) CYTOTOXIC AGENTS CONTAINING NEW STRONGLY ACTIVE TAXANS, AND THEIR THERAPEUTIC APPLICATION
JP2000297046A5 (en) Infection prophylactic / therapeutic agents, anti-endotoxin agents, vaccine adjuvants, and growth promoters
CO5050328A1 (en) SOLVENT SYSTEM FOR THE BEST PENETRATION OF PHARMACEUTICAL COMPOUNDS
ES2071995T3 (en) COMPOSITION FOR MACROPHAGY ACTIVATION.
LeJohn et al. Cytokinins regulate calcium binding to a glycoprotein from fungal cells
EP0271521A1 (en) Lipopolysaccharide and natural factor compositions for anti-tumor therapy and method of treatment
Bertini et al. A novel type of granules observed in toad endothelial cells and their relationship with blood pressure active factors
ES548492A0 (en) PROCEDURE FOR THE PREPARATION OF DRY SUBSTANCES OBTAINABLE BY LYOPHILIZATION
Camussi et al. Porins and lipopolysaccharide stimulate platelet activating factor synthesis by human mesangial cells
Isogai et al. Role of platelet-activating-factor (PAF) on cellular responses after stimulation with leptospire lipopolysaccharide
Nakada et al. Susceptibility of lipids to mercurials
Brom et al. Effect of sodium fluoride on the generation of lipoxygenase products from human polymorphonuclear granulocytes, mononuclear cells and platelets--indication for the involvement of G proteins
AR007020A1 (en) TREATMENT OF ASTHMA WITH TNFR-IG
FR2573077B1 (en) NOVEL THIOSULFONATE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
BR0014192A (en) Dye and antibody conjugates against angiogenesis target structures for intraoperative representation of tumor margin
DE69929189T2 (en) A complex of alpha-fetoprotein (AFP) and a polyunsaturated fatty acid derivative for the treatment of immune deficiency
Krüger et al. Carcinogenic action of dimethylnitrosamine in trout not related to methylation of nucleic acids and protein in vivo
SE9702698D0 (en) Compositions for lubricating and separating tissues and biological membranes
Saito et al. Inhibitory effect of Toxoplasma lysate antigen on the multiplication of transplanted tumor in mice